Cantor Fitzgerald Downgrades GW Pharma (GWPH) to Neutral, Following Acquisition
Tweet
Share
E-mail
Get Alerts GWPH Hot Sheet
Price: $218.96 --0%
Rating Summary:
13 Buy, 7 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 6 | New: 33
Rating Summary:
13 Buy, 7 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 6 | New: 33
Join SI Premium – FREE
Cantor Fitzgerald analyst Charles C. Duncan downgraded GW Pharma (NASDAQ: GWPH) from Overweight to Neutral with a price target of $220.00 (from $147.00).
For an analyst ratings summary and ratings history on GW Pharma click here. For more ratings news on GW Pharma click here.
Shares of GW Pharma closed at $146.25 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Piper Sandler Double Downgrades Myriad Genetics (MYGN) to Underweight, 'Major Strategic Action Likely Needed'
- Macquarie Downgrades Farm Fresh (FFB:MK) to Neutral
- UBS Downgrades AREIT Inc (AREIT:PM) to Neutral
Create E-mail Alert Related Categories
DowngradesRelated Entities
Cantor Fitzgerald, Charles DuncanSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
